Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV009 in R/R CD19-positive hematologic and lymphoid malignancies
NCT07312630Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LV009 in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 3 months. Started Sep 2025; status: recruiting.
02
Drugs
LV009
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07312630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312630.